Neuroblastoma sits in a different clinical landscape in 2026 than it did at the start of the decade. The 2021 Children's Oncology Group (COG) neuroblastoma risk classification reshaped stratification. Anti-GD2 antibody therapy expanded its footprint across the treatment pathway, GD2-directed cellular therapy matured from feasibility to efficacy data, and survivorship infrastructure became part of comprehensive care. The pace of change is not slowing, and the cost of falling behind falls hardest on the high-risk patients who need precise stratification and structured long-term follow-up.
The current standard now spans the 2021 COG risk classifier, FDA-approved anti-GD2 agents with distinct indications, emerging cellular therapy data, ALK-targeted approaches for the actionable molecular subset, and structured survivorship monitoring. Each domain carries specific updates that change how clinicians manage these patients.
How the 2021 COG Risk Classifier Guides Treatment Decisions
Risk stratification is the single most consequential step in neuroblastoma care, determining whether a child receives observation alone or the most intensive treatment in pediatric oncology. The Children's Oncology Group revised its risk classifier in 2021 to harmonize with the International Neuroblastoma Risk Group Staging System and to incorporate segmental chromosomal aberrations alongside MYCN, ploidy, and histology. The version 2 classifier is now operative across COG trial eligibility and treatment assignment.
According to Irwin et al. (2021) in the Journal of Clinical Oncology, the updated classifier reassigned 3.4 percent of previously non-high-risk patients to the high-risk category. The reclassification flows in both directions rather than just upward. In the new version 2 low-risk group, 18.6 percent of patients had been classified as intermediate risk under version 1, and 2.9 percent as high risk.
Several factors drive risk assignment under the current schema. Age at diagnosis, INRGSS stage, MYCN amplification status, tumor histology, ploidy, and segmental chromosomal aberrations at 1p and 11q each contribute to the final classification. MYCN amplification is the single most powerful adverse prognostic marker and pushes most patients into the high-risk category regardless of other features.
Half of neuroblastoma is classified as high-risk, and bone and bone marrow are the most common sites of metastatic disease in children presenting with metastatic neuroblastoma. Among patients with metastatic involvement, 70 percent of metastases involve bone marrow and 55 percent involve cortical bone. The metastatic pattern directly shapes both staging and treatment eligibility, particularly for therapies indicated specifically for bone or bone marrow involvement at relapse.
The classification system will continue to evolve as ALK, TERT, and ATRX biomarkers mature through prospective evaluation. Routine molecular profiling at diagnosis should include MYCN, 1p, 11q, ploidy, and ALK status to support both current risk assignment and trial eligibility.
What the Current Standard of Care Looks Like for High-Risk Neuroblastoma
High-risk neuroblastoma treatment runs through induction chemotherapy, surgical resection, tandem autologous stem cell transplant, radiation, and maintenance immunotherapy. The 18-to-24-month sequence reflects the intensity required to address aggressive disease biology. Two-thirds of patients do not achieve a complete metastatic response during induction therapy, and two-fifths relapse despite intensive multimodal frontline therapy.
Assessment of metastatic disease in bone and bone marrow requires both MIBG imaging and biopsy. MIBG imaging generates the Curie score by subdividing the body into ten regions, nine skeletal and one soft tissue, each scored 0 to 3 for a maximum collective score of 30. An absolute Curie score of 0 to 2 prior to transplant carries more clinical prognostic weight than relative reduction in Curie score from baseline.
Anti-GD2 monoclonal antibody therapy holds positions across the treatment pathway, with two FDA-approved agents addressing distinct settings. Dinutuximab, a chimeric anti-GD2 antibody, anchors frontline maintenance after consolidation in patients who achieved at least a partial response to induction and consolidation therapy.
Naxitamab (DANYELZA) the only FDA-approved humanized anti-GD2 monoclonal antibody, addresses the relapsed or refractory bone or bone marrow setting under accelerated approval. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.
The indication covers pediatric patients one year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who demonstrated a partial response, minor response, or stable disease to prior therapy, in combination with GM-CSF.
The Study 201 initial analysis included 22 efficacy-evaluable patients, with an overall response rate of 45 percent, complete responses in 36 percent, and a median duration of response of 6.2 months. The pre-specified interim analysis expanded the efficacy population to 52 patients, with an overall response rate of 40 percent, complete responses in 29 percent, and a 46 percent overall response rate among 26 patients with incomplete response to induction therapy. DANYELZA carries a boxed warning for serious infusion-related reactions and neurotoxicity, with structured premedication and at least two hours of post-infusion observation built into the protocol.
Where Cellular Therapy Stands After the Final Results of GD2-CART01 for Neuroblastoma
GD2-directed CAR-T moved from feasibility to mature efficacy data over the past three years. Early trials of third-generation GD2-directed CAR-T constructs incorporated an inducible caspase-9 suicide gene as a safety switch, with the goal of rapid control of immune effector cell-associated neurotoxicity through pharmacologic activation. Results in heavily pretreated patients have informed broader strategic thinking about treatment sequencing.
Outcomes appear to favor earlier referral over deferral to a last-line salvage strategy. The pattern reflects a broader move toward integrating cellular platforms earlier in the disease course rather than reserving them for end-stage disease. Pediatric oncology programs evaluating these approaches should review the current trial landscape and eligibility criteria with their cellular therapy partners.
The data also reinforce the case for maintaining open referral channels and trial awareness across institutional networks. A patient who has cycled through three or more prior lines of therapy is in a different position than one referred after first or second relapse. Knowing where the patient stands in that sequence affects the realistic ceiling of any subsequent intervention.
How ALK-Targeted Therapy Addresses the Actionable Molecular Subset
ALK alterations occur in approximately 10 percent of neuroblastoma cases and represent the most established actionable molecular target in the disease. The category includes both ALK mutations and ALK amplifications, each with prognostic and therapeutic implications. ALK alterations fall outside the formal INRG risk schema but increasingly inform treatment decisions.
Lorlatinib, a third-generation ALK inhibitor, has shown activity in children with ALK-altered neuroblastoma in early-phase trials. The drug was designed to overcome the resistance mutations that limit efficacy of earlier-generation ALK inhibitors. Crizotinib and ceritinib showed activity in this population but were limited by the resistance patterns lorlatinib was specifically designed to address.
The Children's Oncology Group has moved to integrate ALK inhibition into frontline therapy for patients with newly diagnosed ALK alterations. The shift moves ALK-directed therapy from a relapsed-and-refractory option to a planned component of risk-adapted frontline care. The approach reflects a broader strategic move toward biomarker-driven treatment selection.
Programs without ALK testing in their diagnostic panel will miss eligibility for trials and approved combinations. Institutional molecular profiling capabilities are increasingly part of the minimum infrastructure for high-risk neuroblastoma care, alongside MYCN, 1p, 11q, and ploidy assessment.
Why Survivorship Infrastructure Is Now Part of Comprehensive Neuroblastoma Care
Improving survival has shifted clinical attention toward managing the long-term consequences of intensive multimodal therapy. Late effects in survivors treated with modern regimens are now well characterized, and findings continue to inform updates to the Children's Oncology Group Long-Term Follow-Up Guidelines. The survivorship framework now sits alongside acute treatment as part of comprehensive neuroblastoma care.
Hearing loss is among the most prevalent late effects, driven primarily by platinum chemotherapy exposure. Cisplatin-induced hearing loss rates vary widely across historical cohorts, and combined cisplatin and myeloablative carboplatin exposure substantially increases the risk of severe hearing loss compared with high-dose cisplatin alone. Audiology surveillance is a structural component of follow-up, not a discretionary referral.
Endocrine toxicity is similarly common, including thyroid dysfunction, premature ovarian failure, and pubertal delay. Cardiac toxicity tied to anthracycline exposure drives the echocardiographic monitoring schedule. Growth failure and underweight status appear frequently enough in modern cohorts to warrant nutritional monitoring throughout and after treatment.
The COG Long-Term Follow-Up Guidelines define the exposure-based screening framework that programs should implement. Audiology, endocrinology, cardiology, and neuropsychology each play structured roles in monitoring and managing late effects. Programs should confirm they are operating against the current version of the guidelines, as new survivorship data continues to refine recommendations for the modern therapy era.
Apply the 2026 Evidence Base to Your Patient Population
Neuroblastoma care in 2026 demands fluency in the 2021 COG version 2 classifier, the approved anti-GD2 agents and their distinct indications, the evolving role of cellular therapy, the ALK-targeted subset, and the survivorship monitoring framework. Each domain shapes clinical decisions in real patient encounters, and the operational requirement is staying current with each.
Full prescribing information, NCCN combination regimen details, and HCP resources for DANYELZA are available at DanyelzaHCP.com.
Sources
Sources
- DANYELZA (naxitamab-gqgk) [package insert]. New York, NY: Y-mAbs Therapeutics, Inc.; 2024. https://labeling.ymabs.com/danyelza
- Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017;35(22):2580-2587. https://pubmed.ncbi.nlm.nih.gov/28471719/
- DuBois SG, Kalika Y, Lukens JN, et al. Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999;21(3):181-189. https://pubmed.ncbi.nlm.nih.gov/10363850/
- Garaventa A, Poetschger U, Valteau-Couanet D, et al. Randomized Trial of Two Induction Therapy Regimens for High-Risk Neuroblastoma: HR-NBL1.5 International Society of Pediatric Oncology European Neuroblastoma Group Study. J Clin Oncol. 2021;39(23):2552-2563. https://ascopubs.org/doi/10.1200/JCO.20.03144
- Pinto N, Naranjo A, Hibbitts E, et al. Predictors of differential response to induction therapy in high-risk neuroblastoma: a report from the Children's Oncology Group. Eur J Cancer. 2019;112:66-79.
- Yanik GA, Parisi MT, Naranjo A, et al. Validation of Postinduction Curie Scores in High-Risk Neuroblastoma: A Children's Oncology Group and SIOPEN Group Report on SIOPEN/HR-NBL1. J Nucl Med. 2018;59(3):502-508. https://jnm.snmjournals.org/content/59/3/502
